EUVIMEDEUVIMED entdecken
LeserbriefOpen Access · CC BY-NC 4.0

Withdrawal of prostacyclin pathway therapies after initiation of sotatercept treatment in patients with pulmonary arterial hypertension

Karen M Olsson, Jan Fuge iD, Da-Hee Park, Jan C Kamp iD, Marius M Hoeper iD

European Respiratory Journal · 2025-06 · 65 (6) · 2500064

DOI: 10.1183/13993003.00064-2025 ↗

Kurz gefasst

Leserbrief in der Zeitschrift European Respiratory Journal, online erschienen am 23.04.2025. Verfasst von Karen M Olsson und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Hannover, Germany. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Extract Triple combination therapy including prostacyclin pathway agents is considered standard of care for patients with advanced pulmonary arterial hypertension (PAH) [1]. However, treatment with prostacyclin pathway agents, especially with parenteral prostacyclin analogues, is associated with considerable side effects, treatment burden, risks, and high costs. In patients’ view, the initiation of parenteral prostacyclin analogues has a major impact on their daily life [2].

Autor:innen und Institutionen

  • Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Hannover, Germany.
  • Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center of Lung Research (DZL), Hannover, Germany.
  • These authors contributed equally.
  • Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Hannover, Germany hoeper.marius@mh-hannover.de.

ORCID-Profile: Jan Fuge, Jan C Kamp, Marius M Hoeper

Zitieren

APA

Olsson, K. M., Fuge, J., Park, D. H., Kamp, J. C., & Hoeper, M. M. (2025). Withdrawal of prostacyclin pathway therapies after initiation of sotatercept treatment in patients with pulmonary arterial hypertension. European Respiratory Journal, 65(6), 2500064. https://doi.org/10.1183/13993003.00064-2025

Vancouver

Olsson KM, Fuge J, Park DH, Kamp JC, Hoeper MM. Withdrawal of prostacyclin pathway therapies after initiation of sotatercept treatment in patients with pulmonary arterial hypertension. European Respiratory Journal. 2025;65(6):2500064. doi:10.1183/13993003.00064-2025

BibTeX
@article{Olsson2025,
  author = {Olsson, Karen M and Fuge, Jan and Park, Da-Hee and Kamp, Jan C and Hoeper, Marius M},
  title = {Withdrawal of prostacyclin pathway therapies after initiation of sotatercept treatment in patients with pulmonary arterial hypertension},
  journal = {European Respiratory Journal},
  year = {2025},
  volume = {65},
  number = {6},
  pages = {2500064},
  doi = {10.1183/13993003.00064-2025}
}
Kostenlos starten →